Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2

Journal of Applied Physiology

Volumn 103, Issue 6, 2007, Pages 2077-2083

  Faress, Jihane A ^a,c   Nethery, David E ^a   Kern, Elizabeth F O ^b,c   Eisenberg, Rosana ^b   Jacono, Frank J ^a,c   Allen, Chris L ^a   Kern, Jeffrey A ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Bleomycin lung injury; HER2 blockade

Indexed keywords

BLEOMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; IN VIVO STUDY; LUNG FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BLEOMYCIN; COLLAGEN; DISEASE MODELS, ANIMAL; LUNG; MALE; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 36849046661     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00239.2007     Document Type: Article

References (33)

1. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41: 467-470, 1988.
2. Bao S, Wang Y, Sweeney P, Chaudhuri A, Doseff AI, Marsh CB, Knoell DL. Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 288: L36-L42, 2005.
3. Barazzone C, Donati YR, Rochat AF, Vesin C, Kan CD, Pache JC, Piguet PF. Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice. Am J Pathol 154: 1479-1487, 1999.
4. Camenisch TD, Schroeder JA, Bradley J, Klewer SE, McDonald JA. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med 8: 850-855, 2002.
5. Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 28: 103-113, 2005.
6. Fischer BM, Cuellar JG, Byrd AS, Rice AB, Bonner JC, Martin LD, Voynow JA. ErbB2 activity is required for airway epithelial repair following neutrophil elastase exposure. FASEB J 19: 1374-1376, 2005.
7. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317-328, 2004.
8. Hardie WD, Kerlakian CB, Bruno MD, Huelsman KM, Wert SE, Glasser SW, Whitsett JA, Korfhagen TR. Reversal of lung lesions in transgenic transforming growth factor alpha mice by expression of mutant epidermal growth factor receptor. Am J Respir Cell Mol Biol 15: 499-508, 1996.
9. Hardie WD, Piljan-Gentle A, Dunlavy MR, Ikegami M, Korfhagen TR. Dose-dependent lung remodeling in transgenic mice expressing transforming growth factor-α. Am J Physiol Lung Cell Mol Physiol 281: L1088-L1094, 2001.
10. Hardie WD, Prows DR, Leikauf GD, Korfhagen TR. Attenuation of acute lung injury in transgenic mice expressing human transforming growth factor-α. Am J Physiol Lung Cell Mol Physiol 277: L1045-L1050, 1999.
11. Inomata S, Takahashi H, Nagata M, Yamada G, Shiratori M, Tanaka H, Satoh M, Saitoh T, Sato T, Abe S. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 15: 461-467, 2004.
12. Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med 174: 550-556, 2006.
13. Jackson JG, St Clair P, Sliwkowski MX, Brattain MG. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64: 2601-2609, 2004.
14. Jenndahl LE, Isakson P, Baeckstrom D. c-erbB2-induced epithelialmesenchymal transition in mammary epithelial cells is suppressed by cell-cell contact and initiated prior to E-cadherin downregulation. Int J Oncol 27: 439-448, 2005.
15. Korfhagen TR, Swantz RJ, Wert SE, McCarty JM, Kerlakian CB, Glasser SW, Whitsett JA. Respiratory epithelial cell expression of human transforming growth factor-alpha induces lung fibrosis in transgenic mice. J Clin Invest 93: 1691-1699, 1994.
16. Liu J, Kern JA. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am J Respir Cell Mol Biol 27: 306-313, 2002.
17. Liu J, Nethery D, Kern JA. Neuregulin-1 induces branching morphogenesis in the developing lung through a P13K signal pathway. Exp Lung Res 30: 465-478, 2004.
18. Madtes DK, Busby HK, Strandjord TP, Clark JG. Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats. Am J Respir Cell Mol Biol 11: 540-551, 1994.
19. Nemzek JA, Ebong SJ, Kim J, Bolgos GL, Remick DG. Keratinocyte growth factor pretreatment is associated with decreased macrophage inflammatory protein-2alpha concentrations and reduced neutrophil recruitment in acid aspiration lung injury. Shock 18: 501-506, 2002.
20. Nethery DE, Moore BB, Minowada G, Carroll J, Faress JA, Kern JA. Expression of mutant human epidermal receptor 3 attenuates lung fibrosis and improves survival in mice. J Appl Physiol 99: 298-307, 2005.
21. Panos RJ, Rubin JS, Csaky KG, Aaronson SA, Mason RJ. Keratinocyte growth factor and hepatocyte growth factor/scatter factor are heparinbinding growth factors for alveolar type II cells in fibroblast-conditioned medium. J Clin Invest 92: 969-977, 1993.
22. Portnoy J, Curran-Everett D, Mason RJ. Keratinocyte growth factor stimulates alveolar type II cell proliferation through the extracellular signal-regulated kinase and phosphatidylinositol 3-OH kinase pathways. Am J Respir Cell Mol Biol 30: 901-907, 2004.
23. Ray P. Protection of epithelial cells by keratinocyte growth factor signaling. Proc Am Thorac Soc 2: 221-225, 2005.
24. Rice AB, Moomaw CR, Morgan DL, Bonner JC. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 155: 213-221, 1999.
25. Schaefer G, Akita RW, Sliwkowski MX. A discrete three-amino acid segment (LVI) at the C-terminal end of kinase-impaired ErbB3 is required for transactivation of ErbB2. J Biol Chem 274: 859-866, 1999.
26. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134: 136-151, 2001.
27. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60-70, 1999.
28. Sugahara K, Iyama K, Kuroda MJ, Sano K. Double intratracheal instillation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats. J Pathol 186: 90-98, 1998.
29. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 63: 5054-5059, 2003.
30. Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, Welsh MJ. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 422: 322-326, 2003.
31. Viget NB, Guery BP, Ader F, Neviere R, Alfandari S, Creuzy C, Roussel-Delvallez M, Foucher C, Mason CM, Beaucaire G, Pittet JF. Keratinocyte growth factor protects against Pseudomonas aeruginosainduced lung injury. Am J Physiol Lung Cell Mol Physiol 279: L1199-L1209, 2000.
32. Yano T, Deterding RR, Simonet WS, Shannon JM, Mason RJ. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol 15: 433-442, 1996.
33. Yi ES, Salgado M, Williams S, Kim SJ, Masliah E, Yin S, Ulich TR. Keratinocyte growth factor decreases pulmonary edema, transforming growth factor-beta and platelet-derived growth factor-BB expression, and alveolar type II cell loss in bleomycin-induced lung injury. Inflammation 22: 315-325, 1998.